The goal ofthe Translational &Clinical Research Program is to bring new insights from Basic Sciences Programs ofthe Siteman Cancer Center into innovative clinical trials that will have an important impact on improving oncologic care for patients. Our particular emphasis is on utilizing information from Signaling Pathways, (eg FGFR2 in endometrial cancer, NF1 in glioblastoma, and RET in thyroid cancer). Genomics (lung cancer, glioblastoma, prostate cancer and rectal cancer), and Oncologic Imaging (prostate cancer, lung and esophageal cancers, and thyroid cancer) for the design, analysis, and interpretation of clinical research trials and studies. Collaborations with the Prevention and Control Program are also fostered by this program and have resulted in grants, publications and clinical projects from areas including prostate cancer screening and co-morbidity studies. The Translational &Clinical Research Program provides the supporting network for an expanding Developmental Therapeutics Program focused on institutional phase 0,1, and II studies. The program also supports disease-based working groups to develop, review, prioritize, and conduct clinical trials research, with special emphasis on working groups in lung, endometrial, prostate, and Gl cancer, and Neuro-Oncology. Furthermore, the Translational &Clinical Research Program will provide training of investigators at all levels of experience and foster educational opportunities including seminars, courses, retreats, journal clubs, workshops, and work-in-progress meetings. The Translational &Clinical Research Program has 74 members from 15 Departments and 2 Schools. The Program is supported by $24,979,138 in funding of which $11,438,989 in NCI funding and $10,835,323 in other peer reviewed funding. In the last grant period, members of the Translational &Clinical Research Program published 1,157 manuscripts, of which 24.90% represent inter-programmatic and 23.43% resulted from intra-programmatic collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Copper, Tara Conway; Jeffe, Donna B; Ahmad, Fahd A et al. (2018) Emergency Information Forms for Children With Medical Complexity: A Qualitative Study. Pediatr Emerg Care :
Stephens, Calvin J; Kashentseva, Elena; Everett, William et al. (2018) Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. Gene Ther 25:139-156
Sharma, Piyush K; Dmitriev, Igor P; Kashentseva, Elena A et al. (2018) Development of an adenovirus vector vaccine platform for targeting dendritic cells. Cancer Gene Ther 25:27-38
Liu, Ying; Colditz, Graham A; Rosner, Bernard A et al. (2018) Comparison of Performance Between a Short Categorized Lifestyle Exposure-based Colon Cancer Risk Prediction Tool and a Model Using Continuous Measures. Cancer Prev Res (Phila) 11:841-848
McGill, Bryan E; Barve, Ruteja A; Maloney, Susan E et al. (2018) Abnormal Microglia and Enhanced Inflammation-Related Gene Transcription in Mice with Conditional Deletion of Ctcf in Camk2a-Cre-Expressing Neurons. J Neurosci 38:200-219
Bauerle, Kevin T; Hutson, Irina; Scheller, Erica L et al. (2018) Glucocorticoid Receptor Signaling Is Not Required for In Vivo Adipogenesis. Endocrinology 159:2050-2061
Garbow, Joel R; Tsien, Christina I; Beeman, Scott C (2018) Preclinical MRI: Studies of the irradiated brain. J Magn Reson 292:73-81
Dodson, Elizabeth A; Hipp, J Aaron; Lee, Jung Ae et al. (2018) Does Availability of Worksite Supports for Physical Activity Differ by Industry and Occupation? Am J Health Promot 32:517-526
Park, Yikyung; Peterson, Lindsay L; Colditz, Graham A (2018) The Plausibility of Obesity Paradox in Cancer-Point. Cancer Res 78:1898-1903

Showing the most recent 10 out of 1244 publications